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Breast cancer risk increases with age and about a third of female breast cancers are diag-
nosed in patients aged older than 70. Breast cancer in the elderly has, however, poorer
outcome with lower survival rate compared to younger subjects. This may be partly
explained by the delay in diagnosis and the ‘under-treatment’ of elderly breast cancer
patients. In this review I try to provide recommendations for screening, surgery, radio-Breast cancer
Cancer treatment
Elderly
Old age
therapy, (neo)adjuvant hormone treatment and chemotherapy, and also the treatment of
metastatic disease. Since large randomised trials usually exclude elderly patients with
breast cancer, there is still an insufﬁcient evidence for the treatment of such patients.
©  2012 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
underdiagnosed and undertreated, and this adversely affects1.  Background
Breast cancer is one of the most common types of cancer
affecting women, accounting for about 6500 new cases annu-
ally in the Czech Republic. Almost one-half of the newly
diagnosed breast cancers occur in women older than 65 years.
Age is the most important risk factor for breast cancer. As the
median age of the general population in Western European
countries steadily increases, occurrence of those diseases
which manifest typically in elderly people (e.g. diabetes and
rheumatic, cardiovascular and pulmonary disease), including
cancer is also on the rise.
Although we  could expect that the elderly will be treated
with similarly intensive treatment as applied in younger age
groups, the elderly patients with breast cancer are frequently
undertreated, even after adjustment for confounding factors,
such as comorbidities, need for social support, and functional
status. Elderly women are less likely to undergo breast con-
serving therapy and axillary lymph node dissection; radiation
therapy (RT) is more  likely to be omitted after breast conserv-
ing surgery and elderly patients also less frequently receive
∗ Tel.: +420 24966751; fax: +420 24966753.
E-mail address: tesarova.petra@seznam.cz
1507-1367/$ – see front matter © 2012 Greater Poland Cancer Centre. Pu
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systemic therapy, particularly chemotherapy. In contrast, the
use of adjuvant hormonal therapy has been reported to be
independent of patient age.
The reasons for these differences in approach to the care
of older patients are probably multifactorial and may include
a higher rate of patient comorbidities, poorer performance
status, limited social support, difﬁculty with transportation,
patient or family preference, concerns about quality of life,
lower life expectancy. In addition, because so few research
studies have included older women, the lack of available evi-
dence may also lead to less aggressive care.
Studies that have examined the predictors of surgery
and adjuvant radiation have found that chronologic age
was associated with substandard therapy independently of
performance status, or comorbidities, suggesting that physi-
cians may be undertreating even otherwise “healthy” elderly
women.
Elderly women with breast cancer are thus consideredtheir overall survival. Most women who die of breast cancer
are much more  frequently older than 65 years of age. Despite
this information, it has been conﬁrmed by many  studies that
blished by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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lderly patients do not receive a standard treatment given to
heir younger counterparts.1
.  Screening  of  breast  cancer  in  elderly
omen
creening is likewise a very controversial issue in the elderly
opulation. There are very few retrospective and prospective
tudies looking speciﬁcally at cancer screening in the elderly.
n the Czech Republic, screening mammography is recom-
ended with or without clinical breast examination (CBE),
very 2 years for women aged 45 and older. Despite this, mam-
ography is not largely used for screening purposes in the
lderly patients with breast cancer, but mostly for diagnosis of
ymptomatic patients. Screening mammography is in general
ot performed in women over 65–70 years.
Some elderly women delay reporting and underreport to
heir physicians suspicious symptoms and lesions and their
reast cancer may then be more  likely to be diagnosed at
 more  advanced stage with putatively reduced treatment
ptions and inferior outcomes. Apparently, breast cancer
wareness should be high especially in the elderly, population
ith the highest risk of developing breast cancer. Breast health
romotion campaigns should include images of older women
o make clear the relevance of this information to women in
his age group.2
.  Biologic  changes  associated  with  aging
ust as aging in the general population alters the demographics
f cancer, aging in the individual patient alters the biology of
ancer. These biologic changes affect the risk of cancer, tumor
ctivity, and the response to treatment.
.  Changes  in  tumorigenesis  and  host
efenses
ncreased risk of cancer in the aging population may be
ttributed mainly to two processes: slowly accruing damage to
NA and progressive decline in host defenses against tumor
rowth. Damage to DNA occurs as a result of cumulative
xposure to carcinogenic chemicals, radiation, and viruses.
nother source of damage are the cumulative effects of
ndogenous processes that lead to the formation of reac-
ive oxygen species, which are highly damaging to cellular
tructures. In summary, carcinogenesis is a time-consuming
rocess. Hence, the incidence of many  types of cancer
ncreases with age. The older the patient, the greater the
otential for DNA damage to be accrued. The greater the
umulative damage to DNA, the greater the potential for
alignancy.
Damage to DNA may take the form of abnormal linkages
ithin and between nucleic acid strands, breaks in nucleic
cid strands, or altered sequence of bases. General damage
ypically leads to cellular senescence (loss of mitotic abil-
ty) and apoptosis (programmed cell death). However, damage
hat involves certain speciﬁc genes may lead to cancer. The
ctivation of oncogenes stimulates tumor growth, while theiotherapy 1 8 ( 2 0 1 3 ) 26–33 27
deactivation of tumor suppressor genes allows cellular growth
to remain uncontrolled.
Aging is associated with decreases in the production and
activity of protective enzymes and hormones with the capac-
ity to repair or bypass damaged DNA, and in immune defenses
against viruses and tumor growth. In addition, damage to
mitochondrial DNA interferes with apoptosis, thus allowing
DNA-damaged cells with malignant potential to persist.
5.  Changes  in  pharmacokinetics
A number of speciﬁc age-related pharmacokinetic changes
may result in an increase in the toxicity of chemotherapy in
older patients. The volume of distribution (Vd) shrinks because
of a decrease in total body water. For drugs that bind to eryth-
rocytes (such as anthracyclines and epipodophyllotoxins), the
Vd will also be affected by anemia, which is common in older
patients with chronic disease. Similarly, hypoproteinemia (in
most cases secondary to inadequate synthesis or excessive
renal loss of albumin and other carrier proteins) can alter the
Vd for numerous drugs that have signiﬁcant binding to albu-
min  and other serum proteins.
While changes in total body water, erythrocyte mass, and
serum protein levels can affect the Vd of chemotherapeutic
drugs, a decrease in the glomerular ﬁltration rate (GFR) can
cause decreased clearance of some drugs. The decrease in the
GFR is due to a gradual loss of nephrons. A lower GFR is of
particular concern in the case of drugs and drug metabolites
whose clearance depends heavily on renal excretion (includ-
ing such drugs as methotrexate, bleomycin, carboplatin and
the daunorubicin metabolite, daunorubinicol).
In addition, renal excretion as a percentage of total excre-
tion varies with each chemotherapeutic drug, and a decrease
in renal excretion may be offset to some degree by an increase
in hepatic excretion. On the other hand, hepatic metabolism
also tends to decrease in older patients owing to reductions
in hepatic blood ﬂow and cytochrome P-450 enzyme system
activity.
To summarize, age-related pharmacokinetic changes can
increase the toxicity of chemotherapeutic drugs, but the
effects tend to be highly variable.
6.  Changes  in  pharmacodynamics
Age-related changes can also affect pharmacodynamics, often
resulting in increased resistance to the anti-tumor activity of
chemotherapeutic drugs.
Elderly people are more  likely to express the multidrug
resistance (MDR) gene, which causes tumor cells to extrude
natural drugs such as antibiotics and plant derivatives, and
this mechanism may account for the drug resistance that
is often seen in older patients with acute myeloid leukemia
(AML). In addition, chemotherapeutic drugs that depend on
inducing apoptosis are less effective if a signiﬁcant proportion
of tumor cells have lost this capacity.
Finally, the tumoricidal effects of chemotherapy and radio-
therapy are the best in well-oxygenated cells that are rapidly
proliferating. Therefore, treatment in older patients may be
nd radiotherapy 1 8 ( 2 0 1 3 ) 26–33
Table 1 – Potential barriers to treatment of older patients
with breast cancer.
Ageism
Paternalism
Generalizations about homogeneity of age
Misunderstandings about life expectancy
Decreased access to care
Decreased screening
Delayed diagnosis
Incomplete staging and assessment
Comorbidity
Few clinical trials28  reports of practical oncology a
less effective, because tumors in this age group are often
relatively anoxic (owing to impaired circulation) and indo-
lent (owing to a natural-selection process, as more-aggressive
tumors typically cause death at an earlier age).
7.  Changes  in  cancer  activity
Aging often involves a decline in tumor aggressiveness and
a corresponding decline in chemotherapy effectiveness. As
stated above, tumor indolence in elderly patients may arise
from a natural-selection process (as patients with more-
aggressive tumors usually die at a younger age) and from
compromised circulation (as poor oxygenation limits cell pro-
liferation).
Aside from these general age-related changes, certain
disease-speciﬁc changes related to aging may also affect
tumor activity and the response to therapy.3
8. Management  decisions  in  elderly
patients  with  cancer
Breast Cancer Care recommends that breast multi-
disciplinary teams (MDTs) consider using comprehensive
geriatric assessment (CGA) tools in the treatment decision-
making process for older women. CGA tools offer a useful
way of making treatment decisions on the basis of functional
status rather than chronological age. We  are also concerned
that many  older women may not be having their information
and support needs adequately assessed and addressed as
part of their breast cancer treatment and care. CGA tools may
also be useful in assessing the psycho-social needs of older
women, for example mental health issues, or help needed
with daily living activities.
It is also important that the treatment decision-making
process adequately takes into account informed preferences
of the patient and the impact of other signiﬁcant factors in that
person’s life. Breast cancer is unlikely to be an older patient’s
only health concern. An older patient is also more  likely to
have a burden of caring responsibilities.
Just as age itself is not an automatic contraindication to
standard cancer treatment, a diagnosis of cancer by itself is
not an automatic indication for treatment. Factors that relate
to both the disease and the patient must be considered in
deciding whether and how to treat the cancer. For example,
chemotherapy in intermediate-grade lymphoma is beneﬁcial
in virtually every circumstance, but the beneﬁt of adjuvant
chemotherapy in breast cancer varies with the likelihood that
the patient will die of the disease. Statistically, chemotherapy
becomes beneﬁcial only when the risk of cancer-related death
exceeds a certain threshold, and that threshold is lower in a
70-year-old woman than in an 80-year-old woman.4
9.  Disease  factorsThe diagnosis and staging of cancer follow standard criteria,
but the patient’s age may affect these assessments. The tumor
cell type indicates its proliferative rate and invasiveness, but
these measures may vary in older patients, as in the previouslyJNCI J Natl Cancer Inst (1993) 85 (3) 190–199.
cited example of breast cancer, which may be less aggressive
but also less responsive to chemotherapy in older women.
Cancer in older patients is often diagnosed at a more
advanced and therefore less treatable stage than in younger
patients. A delayed diagnosis may be due in part to a clinical
bias against aggressive diagnosis in the geriatric population,
and in part to older patients’ reluctance to seek treatment.
10.  Patient  factors
The clinical workup and CGA should document potential
risk factors that could affect the outcome of treatment.
Age-related declines in major physiologic functions (espe-
cially cardiovascular function, renal and hepatic function,
and hematopoietic reserve) may lessen the patient’s ability to
withstand surgery, radiation, and cytotoxic chemotherapy.
Comorbid diseases and functional impairment are clearly
associated with a poorer prognosis.5 Similarly, problems with
mental, emotional, or nutritional status, polypharmacy, and
lack of family or social support can interfere with the effective-
ness and tolerability of treatment, with negative implications
for outcome and survival.6
Patient assessment is more  subjective than tumor assess-
ment, but no less important. The clinician must rely on
estimates of the patient’s life expectancy with and without
cancer treatment, the probable impact of the disease and its
treatment on the patient’s quality of life, and all information
obtained during the CGA. (Table 1).
Chronological age alone should not be a contraindication
to potentially curative or life-prolonging treatment regimens.
Elderly patients represent a heterogeneous population and
differ substantially in age-related physiologic changes that
can affect the safety and efﬁcacy of various therapeutic inter-
ventions. The use of comprehensive geriatric assessment
(CGA) tools beneﬁts both clinician and patient by estimat-
ing life expectancy, screening for ﬁtness for treatment, and
assessing risks and beneﬁts of treatment.
In older women, breast cancer generally tends to have a
more  favorable phenotype, with a lower proliferative rate, ER-
and PR-positive status, and low rate of HER2 overexpression.
Only a small part of those patients have triple-negative dis-
ease, a subtype that accounts for 15% of all types of breast
cancer and occurs in a higher percentage of premenopausal
women. Triple-negative breast cancer confers a poor prognosis
and is a substantial treatment challenge.7
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1.  Role  of  surgery
urgery is the primary component of curative therapy for
arly-stage breast cancer. Appropriately selected older women
olerate breast surgery well. Perioperative morbidity is low,
nd mortality rates range from 0% to 2%. These are related
ore  to comorbidity than chronological age. Older women are
ust as concerned about body image  and cosmesis as younger
omen and should be offered the option of breast conserva-
ion when medically appropriate. For those with signiﬁcant
omorbid illnesses, surgery under local anesthesia may be bet-
er tolerated than general anesthesia. Unlike younger patients,
lder individuals undergoing general anesthesia may experi-
nce short-term cognitive impairment.8
A Cochrane meta-analysis concluded that primary hor-
onal treatment with tamoxifen is inferior to surgery (with
r without hormonal therapy) in terms of local control and
rogression-free survival in medically ﬁt older women and
oes not result in signiﬁcantly better overall survival.9
Despite growing research interest in management of breast
ancer in women over the age of 65, no internationally agreed
ecommendations exist for this population. However, a task
orce from the International Society of Geriatric Oncology
SIOG) has provided evidence-based recommendations for
iagnosis and treatment of breast cancer in elderly individ-
als.
The SIOG task force concluded that women older than 70
ears of age should be offered the same surgical options as
ounger women. Breast-conservation therapy (BCT), lumpec-
omy, axillary lymph node sampling, and postoperative RT are
ecommended as the standard of care for patients of all ages
ith early breast cancer. Studies of elderly women have found
hat they also prefer BCT over mastectomy, and BCT is often
ssociated with better quality of life.
The SIOG panel recommended sentinel lymph node biopsy
or elderly patients with tumors of less than 2–3 cm and no
linical evidence of axillary involvement. In cases that involve
igh-risk tumors or clinical suspicion of axillary lymph node
nvolvement, dissection is recommended to determine appro-
riate adjuvant treatment. According to recommendations
rom the International Society of Geriatric Oncology (SIOG),
entinel lymph node biopsy is preferable to axillary lymph
ode dissection, especially in older patients, who have low-
isk tumors.10
2. Role  of  adjuvant  chemotherapy  and
omprehensive  geriatric  assessment  (CGA)
ccording to the SIOG recommendations, whether to use adju-
ant chemotherapy should be based not on age but on a
ariety of factors, including estimated absolute beneﬁt, life
xpectancy, treatment tolerance, and patient preference.
The National Comprehensive Cancer Network (NCCN)
uidelines for breast cancer management recommend the use
f a geriatric assessment tool when management of patients
ged over 70 years is being planned.
Factors that must be considered when a chemotherapeu-
ic treatment approach is being selected include functioniotherapy 1 8 ( 2 0 1 3 ) 26–33 29
and performance status, comorbidities, geriatric syndromes,
socioeconomic status, nutrition, and polypharmacy. While
there is no standardized CGA, it is generally agreed that any
tool should include the clinically relevant measures, such as
those listed in Table 2.
Adverse tumor-related prognostic factors include tumor
histology and hormonal receptor expression. Other adverse
factors include polypharmacy and >3 active comorbidities.
Elderly patients have decreased bone marrow reserves and
are at a higher risk for chemotherapy-associated neutropenia
and its complications (Table 3). Although guidelines from the
European Organisation for Research and Treatment of Can-
cer (EORTC) and the American Society of Clinical Oncology
(ASCO) speciﬁcally recommend a prophylactic use of colony-
stimulating factors (CSFs) only in patients for whom the
expected rate of febrile neutropenia is 20% or higher, age ≥65
years is itself a risk factor for febrile neutropenia. Although
data are lacking to conﬁrm a survival beneﬁt with these agents
in elderly patients with breast cancer, they do decrease the
incidence of febrile neutropenia and hospitalization. There-
fore, the NCCN recommends their use in older patients.
13.  Role  of  chemotherapy
Anthracycline-containing regimens have been shown to
improve overall survival and relapse rates among node-
positive postmenopausal patients aged <70 years compared
with no anthracyclines. However, the beneﬁts of chemother-
apy are less clear in older individuals.
A large retrospective review of 4 randomized trials that
included patients with lymph node-positive breast cancer
showed similar reductions in breast cancer mortality and
recurrence among younger and older women who  received
chemotherapy, irrespective of hormone receptor activity. In
a phase 3 trial that was conducted speciﬁcally in women
≥65 years of age, weekly epirubicin plus tamoxifen improved
disease-free survival, but not overall survival, when compared
with tamoxifen alone. According to the SIOG recommen-
dations for women with hormone receptor-positive breast
cancer, the beneﬁt of adding chemotherapy to adjuvant hor-
mone treatment is likely to be higher among those with
tumors that are not clearly hormone-sensitive (e.g., they have
low levels of hormone receptors, unknown receptor status, or
high tumor grade).13
The SIOG guidelines recommend 4 courses
of an anthracycline-containing regimen over
cyclophosphamide/methotrexate/5-ﬂuorouracil (CMF) in
elderly patients with breast cancer. As in younger women,
high-risk, ﬁt elderly women may beneﬁt from addition
of a taxane. Among patients with increased cardiac risk,
docetaxel/cyclophosphamide (TC) or CMF  may replace
anthracycline-based therapy.14
Treatment decisions regarding chemotherapy should be
based not on chronological age but on individual patient
factors, including life expectancy, treatment tolerance, esti-
mated absolute beneﬁt, and patient goals and preferences.
In addition to a comprehensive geriatric assessment, such
tools as Adjuvant Online (www.adjuvantonline.com) may help
30  reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 26–33
Table 2 – Comprehensive geriatric assessment.
Factor Tools for assessment Other assessments
Functional status Activities of daily living
Instrumental activities of daily living
Performance status
Comorbidity Charlson Comorbidity Index
Cumulative Illness Rating Scale—Geriatrics
Socioeconomic issues Living  conditions
Caregiver presence and competence
Income
Access to transportation
Nutritional status Mini Nutritional Assessment
Polypharmacy Number of medications
Drug–drug interactions
Geriatric syndromes Geriatric Depression Scale
Folstein Mini Mental Status
Delirium
Falls
Osteoporosis
Neglect and abuse
Failure to thrive
Ref. 11.
Table 3 – Physiologic changes of chemotherapy associated with aging in elderly patients with cancer.
Physiologic change Consequence of chemotherapy
Slower repair of DNA damage Prolonged toxicity
Reduced stem-cell mass and hematopoiesis Slow recovery of blood and mucosal cells
Reduced functional reserve of organ systems Risk for organ failure with additional tissue loss
Reduced gastrointestinal absorptive surfaces, gastric
motility, and gastric secretion
Reduced  drug absorption
Reduced fat-free mass Altered drug distribution
Greater anemia Increased levels of circulating drugs
Decreased liver mass Reduced drug metabolism
Decreased nephrons mass 
Ref. 12.
estimate the beneﬁts of adjuvant treatment, although it has
not been speciﬁcally validated in older patients (Fig. 1).15
The importance of dose intensity in chemotherapy for
breast cancer was established in the landmark study of
Bonadonna et al., a 20-year follow-up of 386 patients who
had been treated with surgery with or without adjuvant
Fig. 1 – Proportion of elderly patients (≥65 years) enrolled
onto registration trials compared with the proportion of
elderly patients in the US cancer population. The
differences between the two groups were  signiﬁcant for all
cancer types except breast cancer (P < .001).
Ref. 17.Reduced drug excretion
chemotherapy consisting of 12 cycles of CMF.  The main
ﬁndings are that survival was signiﬁcantly increased in the
patients who were given adjuvant chemotherapy but the ben-
eﬁt in older women who were given chemotherapy was less
because they were given lower doses. The threshold for ther-
apeutic effectiveness was the delivery of at least 85% of the
planned chemotherapy dose. Subsequent research empha-
sizes the importance of not only total dose delivered but also
dose intensity as a key determinant of outcome in breast can-
cer.
As previously discussed, the main obstacle to delivering an
adequate total dose and maintaining adequate dose intensity
is chemotherapy-induced myelo-suppression and the reliance
on treatment delays and/or dosage modiﬁcations to allow
hematopoietic recovery.16
14.  Role  of  postoperative  RT
Postoperative RT following breast-conserving surgery, com-
bined with appropriate systemic adjuvant treatment, has been
shown to signiﬁcantly reduce both absolute risk for 5-year
recurrence and 15-year absolute breast cancer mortality risk.
Proportional reductions were found in all patients regardless
of age, although absolute risk was lower in older patients.18
No signiﬁcant increase in RT toxicity has been seen
in older women. Therefore, among healthy older women,
d rad
s
i
t
i
b
s
c
e
r
r
w
t
c
t
r
f
i
i
>
n
1
A
h
p
(
p
t
3
i
g
3
n
t
n
8
s
8
t
r
m
a
O
a
t
a
m
b
c
(
Areports of practical oncology an
tandard fractionation RT with a boost to the lumpectomy cav-
ty is considered a standard component of breast-conserving
herapy.
Studies in older women have found no important increase
n RT toxicity. The SIOG panel recommends that RT after
reast-conserving surgery and adjuvant systemic treatment
hould be considered in all older women with breast can-
er. Factors that should be taken into account include life
xpectancy, patient health and functional status, mortality
isk from comorbidities (especially cardiac or vascular), and
isk for local recurrence.19
Since absolute risk for local recurrence is lower in older
omen, the beneﬁts of RT may decline with age. In addi-
ion, the schedule and duration of conventional RT may be
hallenging for older women who  have limited mobility or
ransportation. Alternatives that demonstrate promising early
esults include hypofractionated RT schedules, more  rapid
ractionation, and partial-breast rather than whole-breast
rradiation.20
If adjuvant hormone therapy is planned after lumpectomy,
t may be feasible to omit adjuvant RT in selected women
70 years who  have small (<2 cm), ER-positive, clinically node-
egative breast cancer.21
5. Adjuvant  hormonal  therapy
djuvant hormonal therapy has clear beneﬁts in women with
ormone receptor-positive early breast cancer, but it is under-
rescribed in elderly women.
In the Early Breast Cancer Trialists’ Collaborative Group
EBCTCG) overview analysis of data from women with ER-
ositive breast cancer, 5 years of adjuvant treatment with
amoxifen reduced the annual recurrence rate at 15 years by
4% in women aged 50–59, 45% in women aged 60–69, and 51%
n women older than 70 years. Among patients in these 3 age
roups, the annual death rate was reduced by 24%, 35%, and
7%, respectively. Relative risk reduction was similar for node-
egative compared with node-positive subgroups, although
he absolute magnitude of beneﬁt was higher in women with
ode-positive disease.22
Compared with younger women, those over the age of
0 years are only half as likely to report having a discus-
ion about tamoxifen with their physicians. Women aged
5–92 are 25% less likely to receive a tamoxifen prescription
han those aged 80–84 years. This may be due to concerns
egarding thromboembolic risk, other side effects, and treat-
ent adherence.23,24
Until recently, tamoxifen was the only hormonal ther-
py option for postmenopausal women with breast cancer.
ther data suggest that aromatase inhibitors (AIs), such as
nastrozole, letrozole, or exemestane, are more  effective than
amoxifen.
The enzyme aromatase converts testosterone to estradiol
nd converts androstenedione to estrone, which is the pri-
ary estrogen source in postmenopausal women. AIs have
een shown to signiﬁcantly prolong disease-free survival
ompared with tamoxifen in several studies. In the ATAC
Anastrozole Tamoxifen Alone and in Combination) trial, the
I anastrozole also signiﬁcantly prolonged time to recurrenceiotherapy 1 8 ( 2 0 1 3 ) 26–33 31
and reduced distant metastases and contralateral breast can-
cer compared with tamoxifen. In a subgroup analysis of the
ATAC trial, women aged ≥65 years had a greater beneﬁt from
anastrozole than from tamoxifen (hazard ratio for recurrence,
1.19; 95% CI 1.04–1.36).
In addition, the ATAC trial showed that anastrozole was
associated with a lower risk for ischemic cerebrovascular
events, endometrial cancer, hot ﬂashes, venous thromboem-
bolic events, and vaginal bleeding than tamoxifen, although
it was associated with a higher risk for bone fractures and
musculoskeletal pain. The ATAC trial reported a higher rate
of osteoporosis among women treated with an AI who had
osteopenia at baseline. Therefore, tamoxifen may be the pre-
ferred option in women with preexisting osteoporosis, severe
osteopenia, or a history of fractures. AIs may exacerbate mus-
culoskeletal symptoms in women with severe arthritides or
chronic pain syndromes.25
16.  Managing  AI-induced  osteoporosis
Low BMD is associated with increased risk for fracture, which
can result in limited mobility, depression, loss of indepen-
dence, and chronic pain. Fractures of the hip and spine are
also associated with an approximately 20% increased mor-
tality rate. When AIs are being considered, BMD  assessment
is recommended before initiation of therapy in all women
and especially in those with risk factors for osteopenia or
osteoporosis. Risk factors include small and thin stature,
older age, female gender, a diet low in calcium or vitamin
D, hypothyroidism, smoking, excessive alcohol consumption,
and immobility.
Studies have shown that attention to bone health decreases
the risk for AI-associated osteopenia and osteoporosis. One
study evaluated the impact of early use of bisphosphonates in
602 postmenopausal women receiving adjuvant AI treatment
with letrozole. Patients were randomly assigned to zoledronic
acid 4 mg  every 6 months either up front or delayed until T-
score decreased to less than −2.0 or a nontraumatic fracture
occurred. At 1 year, BMD at the lumbosacral spine was 4.4%
higher in the up-front treatment group.
Another potential beneﬁt of bisphosphonate treatment
in breast cancer is that it appears to have direct cyto-
toxic and antiangiogenic activity. A recent study found that
premenopausal women with early-stage hormone-sensitive
breast cancer derived a signiﬁcant survival beneﬁt when
zoledronic acid was added to adjuvant therapy, even in
patients without bone metastases. Treating physicians must
also carefully consider the risks of bisphosphonate therapy,
which include renal insufﬁciency and irreversible renal fail-
ure, microfractures, myalgias and arthralgias, osteonecrosis,
hypocalcemia, and other electrolyte abnormalities.26
17. Treatment  complianceThe Early Breast Cancer Trialists Collaborative Group meta-
analysis reported improvements in the risk for recurrence and
risk for death with the use of tamoxifen for early breast cancer,
and the pivotal aromatase inhibitor (AI) trials showed further
nd ra32  reports of practical oncology a
improvements in disease-free survival with the use of an AI
over tamoxifen. Further, we see patients undergo chemother-
apy or radiation, coping with such unpleasant side effects
as nausea, skin rash, hair loss, infections, diarrhea, and oral
mucositis, but there is no question of adherence because these
treatments are directly observed. When our patients then shift
to “easier” treatments such as hormonal therapy for breast
cancer, an obvious assumption would be that if a patient can
withstand chemotherapy and radiation, she surely will adhere
to hormonal therapy. A review of the medical literature on this
subject, however, indicates that a surprisingly high percentage
of patients do not fully adhere to treatment as prescribed.
The pivotal AI trials demonstrated a range of hormonal
treatment discontinuation because of toxicity that would ﬁt
the clinical experience of many  medical oncologists (10–14%).
These studies, however, were recording withdrawals based
only on adverse events. A substantial additional number of
patients stop these medications on their own for many  rea-
sons that are completely unrelated to tolerability.
A study from Kaiser Permanente of Northern California
sought to establish adherence by examining prescription reﬁll
data on 8769 patients with breast cancer who ﬁlled pre-
scriptions for tamoxifen only (43%), AI only (29%), or both
(30%) within 1 year of a diagnosis of breast cancer.5 Patients
were considered to be “adherent” if the number of pills
dispensed in prescriptions from the date of the ﬁrst pre-
scription to the end of follow-up covered at least 80% of
the days in the entire period. This statistic is called the
medication possession ratio (MPR). Patients were consid-
ered to have discontinued therapy if a period of 180 days
elapsed from the prior prescription without a reﬁll. Over 4.5
years of follow-up, 32% of all patients discontinued medi-
cation. Of the remaining 68% who continued therapy, only
72% were fully adherent at the end of 4.5 years. Taken
together, their data indicated that, overall, only 49% of
patients were fully adherent (i.e., MPR  > 80%) for the entire
4.5 years. Factors predicting poor adherence included age
<40 or >75 years. Longer prescription reﬁll intervals (i.e.,
90 days) seemed to enhance full adherence to hormonal
therapy.27
Results of the Patient’s Anastrozole Compliance to Ther-
apy (PACT) program were presented for the ﬁrst time at the
2010 meeting of the American Society of Clinical Oncology.
This study aimed to increase treatment adherence in post-
menopausal women taking adjuvant anastrozole through the
provision of a standardized information service. Patients were
randomly assigned to either a group getting standard medical
care or a group getting added education regarding medica-
tion use. The results presented at the meeting revealed an
adherence rate of 88% in both arms, indicating no beneﬁt
to the intervention. Similar results are brought by Cariatide
trial.
18.  Palliative  treatmentAlthough tumoricidal treatment may be given, a palliative
approach to disease management will probably occur. Pal-
liative and supportive care is an integral component of
the management of the elderly breast cancer patients withdiotherapy 1 8 ( 2 0 1 3 ) 26–33
advanced disease. Common problems include pain, cognitive
impairment, depression, lymphoedema and ulcerating dis-
ease. End of life care and dignity therapy are also of great
importance. Elderly patients with breast cancer are a unique
cohort whose nuances with regard to palliative care issues
rightly deserve special consideration.
Because metastatic disease carries an entirely different
prognosis, the treatment goal is also different – palliation
rather than cure. Cytotoxic chemotherapy is reserved for
patients in whom primary endocrine therapy has failed.28
When treating older patients with nearly any disease pro-
cess, it is essential for physicians to understand the speciﬁc
patient’s personal goals for medical care, his or her values
and priorities for quality and quantity of life. This becomes
especially critical as patients develop more  comorbidities and
have declining mental or physical function. When an elderly
patient receives a diagnosis of cancer, the patient and fam-
ily must understand the possibilities for cure, extension of
life, and palliation. Treatment options, and their likelihood of
success, must always be weighed against the risk of adverse
effects and overall impact on quality of life.
Because of the complexity of cancer treatment and ongoing
advances, it is important that every patient with a diagnosis
of cancer be referred to an oncologist to discuss the treatment
options in detail. Ideally, older patients with complex medical
and social issues should be referred to a geriatric oncologist
with experience in caring for elderly patients with cancer. In
the case of a 50-year-old woman diagnosed with cancer with
no comorbid medical problems, the direction for treatment
may be obvious. However, for an 85-year-old with multiple
medical problems, dementia, or physical limitations, the rec-
ommendations for care and treatment become more  complex.
These decisions must involve the patient and family mem-
bers under the guidance of physicians who can understand
and properly evaluate these complexities. Fortunately, dual-
trained geriatric oncologists are becoming more  common as
these issues become clearer to the medical community. In
addition, a shift to a multidisciplinary team approach that
includes oncologists, geriatricians, pharmacists, social work-
ers, and others may be the ideal model to improve the overall
quality of cancer care in the elderly.29
19.  Conclusion
The conclusions on breast cancer in older women are sim-
ilar to those on other forms of cancer in the elderly. The
main determinants of outcome and survival are tumor char-
acteristics and comorbidities, not age itself. Furthermore,
otherwise-healthy older women can and should be treated
with the same standard adjuvant chemotherapy as younger
women.30 There is a strong evidence that older women tend
not to have their breast cancer managed in accordance with
evidence-based national clinical guidelines, often with the
omission of surgery, even when there is no clinical reason
for this conservatism. There is a growing body of evidence
around the usefulness of integrating the principles and prac-
tices of elderly care into oncology. Breast Cancer Care is calling
for older women to be speciﬁcally and effectively targeted by
health promotion campaigns as the people most at risk of
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